logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Oct 19, 2015

PharmaCyte Biotech to Conduct Pancreatic Cancer Clinical Trial in United States

  • Oct 15, 2015

PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial

  • Oct 14, 2015

PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need

  • Oct 9, 2015

Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment

  • Oct 7, 2015

PharmaCyte Biotech CEO in Europe to Secure Orphan Designation With the EMA

  • Oct 5, 2015

Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech’s Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial

  • Oct 1, 2015

PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers

  • Sep 30, 2015

PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial

  • Sep 28, 2015

PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need

  • Sep 25, 2015

PharmaCyte Biotech Hires Industry-Leading Firm to Assist With Investigational New Drug Application

RSS
  • « Previous
  • 1...
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan February 2, 2023
  • PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value October 7, 2022